Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The human genome--chromosome 22]

R Brdicka1

  • 1Ustav hematologie a krevní transfuze, Praha.

Casopis Lekaru Ceskych
|November 15, 1995
PubMed
Summary
This summary is machine-generated.

The Philadelphia chromosome, a derivative of chromosome 22, is linked to chronic myeloid leukemia (CML). Detecting the BCR/ABL fusion gene aids in diagnosing CML, monitoring treatment, and detecting relapses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncolytic viruses and cancer treatment.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2023
Same author

[The substance of genetic information--nucleic acids].

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2012
Same author

Transcriptome alterations in maternal and fetal cells induced by tobacco smoke.

Placenta·2011
Same author

HVRII of mtDNA in cord blood cells of newborn children and in their saliva 10 years later.

Folia biologica·2011
Same author

[Personalized medicine--genomic phase].

Casopis lekaru ceskych·2010
Same author

Effect of maternal tobacco smoke exposure on the placental transcriptome.

Placenta·2010

Area of Science:

  • * Genetics
  • * Molecular Biology
  • * Oncology

Context:

  • * Chromosome 22 is primarily recognized for the Philadelphia chromosome, a hallmark of chronic myeloid leukemia (CML).
  • * The genetic hallmark of CML involves the BCR/ABL fusion gene, resulting from a translocation between chromosomes 9 and 22.

Purpose:

  • * To highlight the significance of the BCR/ABL fusion gene in CML diagnosis and management.
  • * To discuss the role of BCR/ABL detection in monitoring residual disease and early relapse detection.
  • * To mention other significant loci on chromosome 22, including those related to immunoglobulin lambda, crystalline proteins, GM-CSF receptor, myoglobin, and neurofibromatosis type 2.

Summary:

  • * The BCR/ABL fusion gene, formed by the translocation of ABL oncogene (chromosome 9) and BCR gene (chromosome 22), produces a hyperactive ABL kinase.

Related Experiment Videos

  • * Detection of the BCR/ABL transcript is crucial for diagnosing CML and assessing treatment efficacy.
  • * This molecular marker facilitates the investigation of minimal residual disease and the early identification of potential relapses post-treatment or transplantation.

    • Impact:

    • * Improved diagnostic accuracy for chronic myeloid leukemia.
    • * Enhanced patient monitoring strategies through the detection of minimal residual disease.
    • * Facilitation of early relapse detection, enabling timely therapeutic adjustments.